Protalix BioTherapeutics Inc (PLX) concluded trading on Wednesday at a closing price of $1.40, with 0.4 million shares of worth about $0.56 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -22.22% during that period and on June 18, 2025 the price saw a gain of about 2.19%. Currently the company’s common shares owned by public are about 78.13M shares, out of which, 73.81M shares are available for trading.
Stock saw a price change of -10.83% in past 5 days and over the past one month there was a price change of -16.67%. Year-to-date (YTD), PLX shares are showing a performance of -25.53% which increased to 22.81% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.82 but also hit the highest price of $3.10 during that period. The average intraday trading volume for Protalix BioTherapeutics Inc shares is 906.05K. The stock is currently trading -9.88% below its 20-day simple moving average (SMA20), while that difference is down -32.83% for SMA50 and it goes to -24.86% lower than SMA200.
Protalix BioTherapeutics Inc (AMEX: PLX) currently have 78.13M outstanding shares and institutions hold larger chunk of about 11.23% of that.
The stock has a current market capitalization of $111.45M and its 3Y-monthly beta is at -0.22. PE ratio of stock for trailing 12 months is 33.33, while it has posted earnings per share of $0.04 in the same period. It has Quick Ratio of 1.69 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PLX, volatility over the week remained 3.06% while standing at 2.66% over the month.
Analysts are in expectations that Protalix BioTherapeutics Inc (PLX) stock would likely to be making an EPS of 0 in the current quarter, while forecast for next quarter EPS is 0 and it is 0 for next year. For the current quarter EPS, analysts have given the company a lowest target 0 which is 0 at the higher side of the target for the same. Stock’s fiscal year EPS is expected to rise by 612.50% while it is estimated to increase by 126.32% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on June 08, 2020 offering a Buy rating for the stock and assigned a target price range of between $3 and $11 to it. Coverage by Rodman & Renshaw stated Protalix BioTherapeutics Inc (PLX) stock as a Buy in their note to investors on April 17, 2017, suggesting a price target of $5 for the stock. On April 04, 2016, Rodman & Renshaw Initiated their recommendations, while on April 23, 2015, Jefferies Upgrade their ratings for the stock with a price target of $2.60. Stock get a Buy rating from R. F. Lafferty on November 12, 2014.
